市場調查報告書

多囊性卵巢症候群治療市場 - 醫藥品分類·流通管道·各地區:市場規模·佔有率·展望·機會·分析 (2020-2027年)

Polycystic Ovary Syndrome Treatment Market, By Drug Class, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品編碼 968701
出版日期 內容資訊 英文 177 Pages
商品交期: 2-3個工作天內
價格
多囊性卵巢症候群治療市場 - 醫藥品分類·流通管道·各地區:市場規模·佔有率·展望·機會·分析 (2020-2027年) Polycystic Ovary Syndrome Treatment Market, By Drug Class, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2020年09月14日內容資訊: 英文 177 Pages
簡介

本報告提供全球多囊性卵巢症候群治療市場相關調查,提供市場概要,市場趨勢,影響市場的因素分析,需求分析,各市場區隔·各地區的市場分析,價格分析,並提供主要企業簡介等資訊。

目錄

第1章 簡介

第2章 市場展望

  • 報告的說明
    • 市場定義和範圍
  • 摘要整理
    • 市場明細:各醫藥品分類
    • 市場明細:各流通管道
  • 連貫機遇地圖(COM)

第3章 市場動態,法規,及趨勢分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 主要的發展
  • 法規方案
  • PEST分析
  • COVID-19影響分析

第4章 全球多囊性卵巢症候群治療市場:醫藥品分類

  • 簡介
    • 市場佔有率分析(%)
    • 與前一年同期比較成長分析
    • 市場區隔趨勢
  • 口服避孕藥
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率
    • 市場區隔趨勢
  • 胰島素增敏劑
  • 抗憂鬱劑
  • 鳥氨酸脫羧酶抑製劑
  • 芳香酶抑製劑·SERM
  • 利尿劑

第5章 全球多囊性卵巢症候群治療市場:各流通管道

  • 簡介
    • 市場佔有率分析(%)
    • 與前一年同期比較成長分析
    • 市場區隔趨勢
  • 醫院藥局
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率
    • 市場區隔趨勢
  • 零售藥局
  • 線上藥局

第6章 全球多囊性卵巢症候群治療市場:各地區

  • 簡介
    • 市場佔有率分析(%)
    • 與前一年同期比較成長分析
    • 市場區隔趨勢
  • 北美
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率
  • 美國
  • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 法國
    • 西班牙
    • 俄羅斯
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • ASEAN
    • 澳洲
    • 韓國
    • 其他亞太地區
  • 南美
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他南美國家
  • 中東
    • GCC各國
    • 以色列
    • 其他中東
  • 非洲
    • 北非
    • 中非
    • 南非

第7章 競爭情形

  • 企業簡介
    • Sanofi Plc
    • Novartis AG
    • Teva Pharmaceutical Industries Limited
    • Addex Therapeutics Ltd.
    • BIOCAD
    • Merck & Co., Inc.
    • AstraZeneca plc
    • Bristol Myers Squibb Co.
    • Ferring Pharmaceuticals, Inc.
    • Crinetics Pharmaceuticals, Inc.

第8章 章節

目錄

Title:
Polycystic Ovary Syndrome Treatment Market, By Drug Class (Oral contraceptives, Insulin Sensitizing Agents, Anti-Depressants, Ornithine Decarboxylase Inhibitors, Aromatase Inhibitors & SERMs, Diuretics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Polycystic ovary syndrome can be explained as set of symptoms such as insulin sensitivity, menstrual regulatory, infertility, acne, and excess body and facial hair, which occurs due to increased levels of male hormone i.e. androgens in females of child-bearing age (15 to 49 years). Polycystic ovary syndrome is an incurable diseases, however, it can be managed by various options such as lifestyle changes, reducing weight, and taking medicines.

Restraints of the Global Polycystic Ovary Syndrome Treatment Market

Major factors hampering the growth of the polycystic ovary syndrome treatment market during the forecast period constitutes of unavailability of FDA approved drugs, and alternative treatment options.

Key features of the study:

  • This report provides in-depth analysis of the global polycystic ovary syndrome treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020-2027), considering 2019, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global polycystic ovary syndrome treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Sanofi, Novartis AG, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD, Merck & Co., Inc., AstraZeneca plc., Bristol Myers Squibb Co., Ferring Pharmaceuticals, Inc., and Crinetics Pharmaceuticals, Inc.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global polycystic ovary syndrome treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Polycystic Ovary Syndrome Treatment Market, By Drug Class:
    • Oral contraceptives
    • Insulin Sensitizing Agents
    • Anti-Depressants
    • Ornithine Decarboxylase Inhibitors
    • Aromatase Inhibitors & SERMs
    • Diuretics
  • Global Polycystic Ovary Syndrome Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Polycystic Ovary Syndrome Treatment Market, By Geography:
    • North America
  • By Drug Class
    • Oral contraceptives
    • Insulin Sensitizing Agents
    • Anti-Depressants
    • Ornithine Decarboxylase Inhibitors
    • Aromatase Inhibitors & SERMs
    • Diuretics
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • U.S.
    • Canada
    • Europe
  • By Drug Class
    • Oral contraceptives
    • Insulin Sensitizing Agents
    • Anti-Depressants
    • Ornithine Decarboxylase Inhibitors
    • Aromatase Inhibitors & SERMs
    • Diuretics
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
  • By Drug Class
    • Oral contraceptives
    • Insulin Sensitizing Agents
    • Anti-Depressants
    • Ornithine Decarboxylase Inhibitors
    • Aromatase Inhibitors & SERMs
    • Diuretics
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Latin America
  • By Drug Class
    • Oral contraceptives
    • Insulin Sensitizing Agents
    • Anti-Depressants
    • Ornithine Decarboxylase Inhibitors
    • Aromatase Inhibitors & SERMs
    • Diuretics
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Middle East:
  • By Drug Class
    • Oral contraceptives
    • Insulin Sensitizing Agents
    • Anti-Depressants
    • Ornithine Decarboxylase Inhibitors
    • Aromatase Inhibitors & SERMs
    • Diuretics
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • By Drug Class
    • Oral contraceptives
    • Insulin Sensitizing Agents
    • Anti-Depressants
    • Ornithine Decarboxylase Inhibitors
    • Aromatase Inhibitors & SERMs
    • Diuretics
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country/Region:
    • Central Africa
    • South Africa
    • North Africa
  • Company Profiles
    • Sanofi Plc*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
    • Novartis AG
    • Teva Pharmaceutical Industries Limited
    • Addex Therapeutics Ltd.
    • BIOCAD
    • Merck & Co., Inc.
    • AstraZeneca plc.
    • Bristol Myers Squibb Co.
    • Ferring Pharmaceuticals, Inc.
    • Crinetics Pharmaceuticals, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

    • Research Objectives
    • Assumptions
    • Abbreviations

2. Market Purview

    • Report Description
  • Market Definition and Scope
    • Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Distribution Channel
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • COVID-19 Impact Analysis

4. Global Polycystic Ovary Syndrome Treatment Market, By Drug Class, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Oral contraceptives
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Insulin Sensitizing Agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Anti-Depressants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Ornithine Decarboxylase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Aromatase Inhibitors & SERMs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Diuretics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends

5. Global Polycystic Ovary Syndrome Treatment Market, By Distribution Channel, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

6. Global Polycystic Ovary Syndrome Treatment Market, By Regions, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • U.S.
    • Canada
    • Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

7. Competitive Landscape

    • Company Profiles
  • Sanofi Plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Teva Pharmaceutical Industries Limited
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Addex Therapeutics Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • BIOCAD
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck & Co., Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AstraZeneca plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bristol Myers Squibb Co.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Ferring Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Crinetics Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

8. Section

    • References
    • Research Methodology
    • About us and Sales Contact